TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

NEUROCRINE

DermatologyNeurology
Pharma

NEUROCRINE is a pharmaceutical company focused on Dermatology, Neurology. Key products include INGREZZA SPRINKLE.

2017
Since
3
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

INGREZZA SPRINKLE
valbenazine tosylate
CNS
VMAT2 3 indications · 2024
INGREZZA
valbenazine tosylate
CNS
VMAT2 2 indications · 2017
CRENESSITY
crinecerfont
CRF1R 1 indications · 2024

Recent Activity

INGREZZA 2025-02-04
Labeling
CRENESSITY 2024-12-13
Type 1 - New Molecular Entity
CRENESSITY 2024-12-13
Type 3 - New Dosage Form
INGREZZA 2024-11-22
Labeling
INGREZZA SPRINKLE 2024-04-30
Type 3 - New Dosage Form
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Dermatology 81%
2 drugs Phase 3: 3 Phase 2: 1 Phase 1: 4
Neurology 19%
0 drugs Phase 2: 2 Phase 1: 3

Pipeline Strength Pro

Loading...

Competitors Pro

Eli Lilly big-pharma
Neurology, Dermatology
LEDERLE big-pharma
Neurology, Dermatology
PAI HOLDINGS PHARM big-pharma
Dermatology, Neurology
ABBOTT big-pharma
Dermatology, Neurology
OTSUKA big-pharma
Neurology, Dermatology